EF Juniper, PR Johnston, CM Borkhoff, GH Guyatt, LP Boulet and A Haukioja
Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, Ontario, Canada.

Most clinical trials in asthma have focused on outcomes that are primarily of importance to the clinician. Very few have assessed whether patients feel better and can function better in day-to-day activities. The aim of this study was to compare the effects of salmeterol (50 micrograms twice daily), salbutamol (200 micrograms four times a day), and placebo on asthma-specific quality of life and to relate the findings to conventional clinical asthma outcomes. The study was a 12-wk multicenter, double blind, randomized, placebo-controlled crossover trial with each trial medication taken for 4 wk. The subjects were 140 adults with mild to moderate asthma enrolled from 14 respiratory clinics across Canada. Outcome measures were: (1) the Asthma Quality of Life Questionnaire and spirometry at the end of each treatment period; and (2) daily asthma symptoms, morning and evening peak expiratory flow rates (PEFRs), and rescue salbutamol use during the last 14 d of each treatment period. Asthma-specific quality of life, both overall and for the individual domains (activity limitation, symptoms, emotional function, and exposure to environmental stimuli) was better with salmeterol than with placebo (p < 0.0001), and better with salmeterol than with salbutamol (p < 0.001). In both comparisons, differences were not only statistically significant, but most were also clinically important. There were moderate correlations between change in quality of life and change in clinical outcomes.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				D. W. Denning, B. R. O'Driscoll, G. Powell, F. Chew, G. T. Atherton, A. Vyas, J. Miles, J. Morris, and R. M. Niven Randomized Controlled Trial of Oral Antifungal Treatment for Severe Asthma with Fungal Sensitization: The Fungal Asthma Sensitization Trial (FAST) Study Am. J. Respir. Crit. Care Med., January 1, 2009; 179(1): 11 - 18. [Abstract] [Full Text] [PDF]

				D. Wensley and M. Silverman Peak Flow Monitoring for Guided Self-management in Childhood Asthma: A Randomized Controlled Trial Am. J. Respir. Crit. Care Med., September 15, 2004; 170(6): 606 - 612. [Abstract] [Full Text] [PDF]

				E.F. Juniper, M.E. Wisniewski, F.M. Cox, A.H. Emmett, K.E. Nielsen, and P.M. O'Byrne Relationship between quality of life and clinical status in asthma: a factor analysis Eur. Respir. J., February 1, 2004; 23(2): 287 - 291. [Abstract] [Full Text] [PDF]

				R. Buhl, G. Hanf, M. Soler, G. Bensch, J. Wolfe, F. Everhard, K. Champain, H. Fox, and J. Thirlwell The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma Eur. Respir. J., November 1, 2002; 20(5): 1088 - 1094. [Abstract] [Full Text] [PDF]

				M. D. Eisner, E. H. Yelin, L. Trupin, and P. D. Blanc The Influence of Chronic Respiratory Conditions on Health Status and Work Disability Am J Public Health, September 1, 2002; 92(9): 1506 - 1513. [Abstract] [Full Text] [PDF]

				E. F. Juniper, D. B. Price, P. A. Stampone, J. P. H. M. Creemers, S. J. M. Mol, and P. Fireman Clinically Important Improvements in Asthma-Specific Quality of Life, But No Difference in Conventional Clinical Indexes in Patients Changed From Conventional Beclomethasone Dipropionate to Approximately Half the Dose of Extrafine Beclomethasone Dipropionate* Chest, June 1, 2002; 121(6): 1824 - 1832. [Abstract] [Full Text] [PDF]

				P. N. BLACK, F. BLASI, C. R. JENKINS, R. SCICCHITANO, G. D. MILLS, A. R. RUBINFELD, R. E. RUFFIN, P. R. MULLINS, J. DANGAIN, B. C. COOPER, et al. Trial of Roxithromycin in Subjects with Asthma and Serological Evidence of Infection with Chlamydia pneumoniae Am. J. Respir. Crit. Care Med., August 15, 2001; 164(4): 536 - 541. [Abstract] [Full Text] [PDF]

				R. F. Lemanske Jr, C. A. Sorkness, E. A. Mauger, S. C. Lazarus, H. A. Boushey, J. V. Fahy, J. M. Drazen, V. M. Chinchilli, T. Craig, J. E. Fish, et al. Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial JAMA, May 23, 2001; 285(20): 2594 - 2603. [Abstract] [Full Text] [PDF]

				M. Eccles, N. Rousseau, B. Higgins, and L. Thomas Evidence-based guideline on the primary care management of asthma Fam. Pract., April 1, 2001; 18(2): 223 - 229. [Full Text] [PDF]

				L D Rimington, D H Davies, D Lowe, and M G Pearson Relationship between anxiety, depression, and morbidity in adult asthma patients Thorax, April 1, 2001; 56(4): 266 - 271. [Abstract] [Full Text]

				M. L. MOY, E. ISRAEL, S. T. WEISS, E. F. JUNIPER, L. DUBÉ, J. M. DRAZEN, and the NHLBI Asthma Clinical Rese Clinical Predictors of Health-related Quality of Life Depend on Asthma Severity Am. J. Respir. Crit. Care Med., March 15, 2001; 163(4): 924 - 929. [Abstract] [Full Text]

				L. M. OSMAN, C. CALDER, R. ROBERTSON, J. A. R. FRIEND, J. S. LEGGE, and J. GRAHAM DOUGLAS Symptoms, Quality of Life, and Health Service Contact among Young Adults with Mild Asthma Am. J. Respir. Crit. Care Med., February 1, 2000; 161(2): 498 - 503. [Abstract] [Full Text]

				E. F. Juniper and A. S. Buist Health-Related Quality of Life in Moderate Asthma: 400 {micro}g Hydrofluoroalkane Beclomethasone Dipropionate vs 800 {micro}g Chlorofluorocarbon Beclomethasone Dipropionate Chest, November 1, 1999; 116(5): 1297 - 1303. [Abstract] [Full Text] [PDF]

				R. F. Lockey, L. M. DuBuske, B. Friedman, V. Petrocella, F. Cox, and K. Rickard Nocturnal Asthma: Effect of Salmeterol on Quality of Life and Clinical Outcomes Chest, March 1, 1999; 115(3): 666 - 673. [Abstract] [Full Text] [PDF]

				N. K. LEIDY, K. S. CHAN, and C. COUGHLIN Is the Asthma Quality of Life Questionnaire a Useful Measure for Low-income Asthmatics? Am. J. Respir. Crit. Care Med., October 1, 1998; 158(4): 1082 - 1090. [Abstract] [Full Text] [PDF]

				J. RANDALL CURTIS, G. D. RUBENFELD, and L. D. HUDSON Training Pulmonary and Critical Care Physicians in Outcomes Research . Should We Take the Challenge? Am. J. Respir. Crit. Care Med., April 1, 1998; 157(4): 1012 - 1015. [Full Text] [PDF]

				G. H Guyatt, E. F Juniper, S. D Walter, L. E Griffith, and R. S Goldstein Interpreting treatment effects in randomised trials BMJ, February 28, 1998; 316(7132): 690 - 693. [Full Text]

				J. R. CURTIS, D. P. MARTIN, and T. R. MARTIN Patient-assessed Health Outcomes in Chronic Lung Disease . What are They, How Do They Help Us, and Where Do We Go From Here? Am. J. Respir. Crit. Care Med., October 1, 1997; 156(4): 1032 - 1039. [Full Text] [PDF]

				Using {beta}2-stimulants in asthma DTB, January 1, 1997; 35(1): 1 - 4. [Abstract] [Full Text] [PDF]

				H. S. Nelson {beta}-Adrenergic Bronchodilators N. Engl. J. Med., August 24, 1995; 333(8): 499 - 507. [Full Text] [PDF]

				SALMETEROL, SALBUTAMOL, AND QUALITY OF LIFE IN ASTHMA. Journal Watch (General), January 24, 1995; 1995(124): 4 - 4. [Full Text]